Kinase Inhibitors

(-)-Enitociclib ((R)-Enitociclib) is an enanthiomer of BAY-1251152 with rotation (-). BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor.Form:SolidIC50&amp: Target:CDK9.

(-)-Enitociclib ((R)-Enitociclib) is an enanthiomer of BAY-1251152 with rotation (-). BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor.Form:SolidIC50&amp: Target:CDK9.

(-)-Enitociclib ((R)-Enitociclib) is an enanthiomer of BAY-1251152 with rotation (-). BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor.Form:SolidIC50&amp: Target:CDK9.

(-)-JNJ-A07 is a potent and selective DENV inhibitor with an EC 50 value of 31 nMForm:SolidIC50&amp: Target:EC 50 : 31 nM (DENV).

(-)-JNJ-A07 is a potent and selective DENV inhibitor with an EC 50 value of 31 nMForm:SolidIC50&amp: Target:EC 50 : 31 nM (DENV).

(-)-JNJ-A07 is a potent and selective DENV inhibitor with an EC 50 value of 31 nMIC50&amp: Target:EC 50 : 31 nM (DENV).

(-)-Zuonin A (D-Epigalbacin), a naturally occurring lignin, is a potent, selective JNKs inhibitor, with IC 50 s of 1.7 μM, 2.9 μM and 1.74 μM for JNK1 , JNK2 and JNK3 , respectivelyIn Vitro(−)-zuonin A binds the D-recruitment site (DRS) of JNK, a

(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective JAK3 inhibitor ( IC 50 =144.8 nM) extracted from patent US20150158864A1, example 68Form:SolidIC50&amp: Target:JAK3 144.8 nM (IC 50 ).

(2S,3R)-Voruciclib hydrochloride is the enantiomer of Voruciclib hydrochloride. (2S,3R)-Voruciclib is an orally active CDK inhibitor.Biological Activity:(2S,3R)-Voruciclib hydrochloride is the enantiomer of Voruciclib hydrochloride.

Tofacitinib(CP-690550) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.

Tofacitinib(CP-690550) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.

Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.